Continue to Site

Drug Discovery and Development

Remington-Davis launches dedicated COVID-19 research unit in Ohio

By |

Remington-DavisClinical research outfit Remington-Davis recently announced that it has launched a dedicated 3,000 ft2 space in Columbus, Ohio for COVID-19 clinical trials.

The space includes six private overnight rooms, patient lounge, dedicated laboratory, oxygen therapy and more. Participants must be 18 or older with COVID-19 symptoms and have a laboratory-confirmed SARS-CoV2 infection.

“We were not able to see our regular research patients and COVID patients in the same space, so we opened a new location dedicated to COVID studies,” said Remington-Davis director Hamish Baird.

Clinical trials have started for REGN-COV2, Regeneron’s anti-viral antibody cocktail for the treating and preventing COVID-19.

Filed Under: clinical trials, Drug Discovery
Tagged With: , ,
 

About The Author

Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at [email protected]

Tell Us What You Think!

Related Articles Read More >

Search Drug Discovery & Development